search
Back to results

Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects

Primary Purpose

Caffeine, Biomechanics, Fatigue

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Caffeine.
Cellulose.
Sponsored by
University of Vic - Central University of Catalonia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Caffeine focused on measuring Ergogenic aids, Kinematics, Kinetics, Neuromuscular fatigue, Acute and chronic injuries, Jump, Squat, Running

Eligibility Criteria

18 Years - 30 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: An uninterrupted training time of at least 1 year in the subjects' regular exercise modality (either the person is still training or interrupted the training period during the last year, and with no more than 4 months of detraining). A good exercise technique of the assessed movement patterns (running, squatting, and jumping). Exclusion Criteria: Not being 18-30 years old. Having any relevant medical condition. Pregnancy. Smoking. Regular medication consumption / Medication consumption the days before the sessions during the study. Other supplementation regular consumption / Other supplementation consumption during the study (excluding sports foods, provided that their goal and nutrients have the objective of substituting the ingestion of regular food (e.g., isotonic drinks, carbohydrates gels, protein powder...), without adding other components that may act as ergogenic substances). Habitual caffeine consumption of >25mg/day-0,99mg/kg/day.

Sites / Locations

  • University of Vic - Central University of Catalonia.Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Control - caffeine - placebo.

Control - placebo - caffeine.

Arm Description

The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one.

The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one.

Outcomes

Primary Outcome Measures

Knee flexion angle at the midstance while running.
Assessment of the knee flexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Ankle dorsiflexion angle at the midstance while running.
Assessment of the ankle dorsiflexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Step rate while running.
Assessment of the step rate (in steps/minute). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Contact time while running.
Assessment of the time the foot is in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Stride length while running.
Assessment of the distance between two successive placements of the same foot (in meters). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Flight time while running.
Assessment of the time the foot is not in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Running performance modification.
Assessment of the time (in seconds) required to complete a specific distance running on a treadmill. The measurement will be done before and after a fatiguing protocol. Assessed using a stopwatch.
Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Assessment of the hip angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Assessment of the knee angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Assessment of the ankle angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Execution time while squatting, for the eccentric and the concentric phases of the movement.
Assessment of the execution time to perform the eccentric and the concentric phases of the squat (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Peak vertical force while squatting, for the eccentric and the concentric phases of the movement.
Assessment of the peak vertical force (in Newtons). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Rate of force development while squatting, for the eccentric and the concentric phases of the movement.
Assessment of the rate of force development (in Newtons/seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Squatting performance modification.
Assessment of the mean propulsive bar velocity (in meters/seconds) for a specific weight lifted in barbell back squats. The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase.
Assessment of the contralateral pelvic drop angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments.
Assessment of the knee valgus angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Unweighting phase duration while jumping (jumping phase).
Assessment of the unweighting phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Braking phase duration while jumping (jumping phase).
Assessment of the braking phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Propulsive phase duration while jumping (jumping phase).
Assessment of the propulsive phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Relative peak power output while jumping (jumping phase).
Assessment of the relative peak power output (in Watts/kg). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Jumping performance modification.
Assessment of the height (in meters) of countermovement jumps. The measurement will be done before and after a fatiguing protocol. Assessed using force plates.

Secondary Outcome Measures

Supplementation identification.
Assessment of the participants' perception regarding the ingested substance. They will have to complete a questionnaire immediately before (1 hour post-supplementation) and after the assessed exercises, indicating what substance they believe that they have consumed, with the options "caffeine", "placebo", or "I don't know", as well as the reason why they have chosen that answer.
Side effects.
Assessment of the participant's side effects related to caffeine consumption. In the morning of the day after the sessions, they will be requested to complete a questionnaire comprised of 8 questions with a yes/no answer, to evaluate the side effects of caffeine consumption during the hours after the sessions.

Full Information

First Posted
September 1, 2023
Last Updated
October 9, 2023
Sponsor
University of Vic - Central University of Catalonia
Collaborators
Generalitat de Catalunya, European Union
search

1. Study Identification

Unique Protocol Identification Number
NCT06039358
Brief Title
Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects
Official Title
Influence of 6mg/kg of Caffeine Supplementation on the Technical Execution of General Movement Patterns Performed by Healthy Subjects, With and Without Neuromuscular Fatigue: a Randomized, Double-blind, Placebo-controlled, Crossover Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 6, 2023 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Vic - Central University of Catalonia
Collaborators
Generalitat de Catalunya, European Union

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic aid with strong evidence regarding its efficacy and that is apparently safe. The beneficial effect of this substance on physical and cognitive performance has been identified in aerobic and anaerobic efforts, including aerobic and muscular endurance, power, or strength. However, it seems that the benefits of caffeine are usually measured only by its effect on performance, while a comprehensive analysis of its impact on other aspects of the movement technique of the exercise is not considered. Therefore, although caffeine generates better performance, a null or negative effect may occur on technique execution. As such, some consequences might arise (e.g., an increase in injury risk or a decrease in energy efficiency). The objective of this randomized controlled trial is to assess the influence of caffeine on certain biomechanical parameters of the technique of physical exercises in circumstances without fatigue and under neuromuscular fatigue. The study hypothesis is that caffeine generates modifications in the technical execution of certain movements in fatigued and unfatigued circumstances due to its physiological effects, which may be beneficial for performance and injury prevention. The participants will have to attend 5 sessions (enrollment, familiarization, control, placebo, and caffeine), at least 7 days apart. In the last 3 sessions, different measurements will be done to their technique while jumping, squatting, and running, without fatigue and with it. Other data will be collected throughout the study to contextualize and analyze in more detail the obtained information.
Detailed Description
A detailed description of the study can be found in the protocol uploaded with this registry entry.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Caffeine, Biomechanics, Fatigue, Injuries, Physical Activity
Keywords
Ergogenic aids, Kinematics, Kinetics, Neuromuscular fatigue, Acute and chronic injuries, Jump, Squat, Running

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The assessed sessions, which will be identical, will be the control, the caffeine, and the placebo ones. The last two sessions mentioned will be performed in a randomized order.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
The placebo and the caffeine ingestion protocols will be identical in format and presentation. To minimize any influence of the flavor or the look of the ingested substance, both conditions will imply the consumption of opaque capsules (ingested with water) in which there will be 6mg/kg of caffeine or placebo.
Allocation
Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control - caffeine - placebo.
Arm Type
Experimental
Arm Description
The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one.
Arm Title
Control - placebo - caffeine.
Arm Type
Experimental
Arm Description
The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one.
Intervention Type
Dietary Supplement
Intervention Name(s)
Caffeine.
Intervention Description
Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Intervention Type
Drug
Intervention Name(s)
Cellulose.
Other Intervention Name(s)
Placebo.
Intervention Description
Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Primary Outcome Measure Information:
Title
Knee flexion angle at the midstance while running.
Description
Assessment of the knee flexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Ankle dorsiflexion angle at the midstance while running.
Description
Assessment of the ankle dorsiflexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Step rate while running.
Description
Assessment of the step rate (in steps/minute). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Contact time while running.
Description
Assessment of the time the foot is in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Stride length while running.
Description
Assessment of the distance between two successive placements of the same foot (in meters). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Flight time while running.
Description
Assessment of the time the foot is not in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Running performance modification.
Description
Assessment of the time (in seconds) required to complete a specific distance running on a treadmill. The measurement will be done before and after a fatiguing protocol. Assessed using a stopwatch.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Description
Assessment of the hip angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Description
Assessment of the knee angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Description
Assessment of the ankle angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Execution time while squatting, for the eccentric and the concentric phases of the movement.
Description
Assessment of the execution time to perform the eccentric and the concentric phases of the squat (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Peak vertical force while squatting, for the eccentric and the concentric phases of the movement.
Description
Assessment of the peak vertical force (in Newtons). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Rate of force development while squatting, for the eccentric and the concentric phases of the movement.
Description
Assessment of the rate of force development (in Newtons/seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Squatting performance modification.
Description
Assessment of the mean propulsive bar velocity (in meters/seconds) for a specific weight lifted in barbell back squats. The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase.
Description
Assessment of the contralateral pelvic drop angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments.
Description
Assessment of the knee valgus angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Unweighting phase duration while jumping (jumping phase).
Description
Assessment of the unweighting phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Braking phase duration while jumping (jumping phase).
Description
Assessment of the braking phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Propulsive phase duration while jumping (jumping phase).
Description
Assessment of the propulsive phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Relative peak power output while jumping (jumping phase).
Description
Assessment of the relative peak power output (in Watts/kg). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Jumping performance modification.
Description
Assessment of the height (in meters) of countermovement jumps. The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Time Frame
During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Secondary Outcome Measure Information:
Title
Supplementation identification.
Description
Assessment of the participants' perception regarding the ingested substance. They will have to complete a questionnaire immediately before (1 hour post-supplementation) and after the assessed exercises, indicating what substance they believe that they have consumed, with the options "caffeine", "placebo", or "I don't know", as well as the reason why they have chosen that answer.
Time Frame
During the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Title
Side effects.
Description
Assessment of the participant's side effects related to caffeine consumption. In the morning of the day after the sessions, they will be requested to complete a questionnaire comprised of 8 questions with a yes/no answer, to evaluate the side effects of caffeine consumption during the hours after the sessions.
Time Frame
During the day after the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: An uninterrupted training time of at least 1 year in the subjects' regular exercise modality (either the person is still training or interrupted the training period during the last year, and with no more than 4 months of detraining). A good exercise technique of the assessed movement patterns (running, squatting, and jumping). Exclusion Criteria: Not being 18-30 years old. Having any relevant medical condition. Pregnancy. Smoking. Regular medication consumption / Medication consumption the days before the sessions during the study. Other supplementation regular consumption / Other supplementation consumption during the study (excluding sports foods, provided that their goal and nutrients have the objective of substituting the ingestion of regular food (e.g., isotonic drinks, carbohydrates gels, protein powder...), without adding other components that may act as ergogenic substances). Habitual caffeine consumption of >25mg/day-0,99mg/kg/day.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arnau Baena Riera, MSc.
Phone
+34 938 861 222
Email
arnau.baena@uvic.cat
First Name & Middle Initial & Last Name or Official Title & Degree
Javier PeΓ±a LΓ³pez, Ph.D.
Phone
+34 938 861 222
Email
javier.pena@uvic.cat
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arnau Baena Riera, MSc.
Organizational Affiliation
Sport, Exercise, and Human Movement (SEaHM), University of Vic - Central University of Catalonia.
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Vic - Central University of Catalonia.
City
Vic.
State/Province
Barcelona.
ZIP/Postal Code
08500.
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arnau Baena Riera, MSc.
First Name & Middle Initial & Last Name & Degree
Javier PeΓ±a LΓ³pez, Ph.D.
First Name & Middle Initial & Last Name & Degree
Xantal BorrΓ s Boix, Ph.D.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects

We'll reach out to this number within 24 hrs